Soltész S, Mencke T, Mey C, Röhrig S, Diefenbach C, Molter G P
Department of Anaesthesia and Intensive Care, Hospital Leverkusen, Am Gesundheitspark 11, D-51375 Leverkusen, Germany.
Br J Anaesth. 2008 Jun;100(6):798-802. doi: 10.1093/bja/aen084. Epub 2008 Apr 9.
Corticosteroids interact with neuromuscular blocking agents. However, experimental data are contradictory: enhancement and attenuation of the neuromuscular block has been observed. This study tested the influence of long-term medication with prednisolone on atracurium-induced neuromuscular block.
Sixty patients with chronic inflammatory bowel disease undergoing elective abdominal surgery were investigated. Thirty patients received a long-term medication with prednisolone (Group A) and 30 were without corticoid medication (Group B). Additionally, another 30 patients without inflammatory bowel disease and without corticoid medication served as control (Group C). The following parameters of an atracurium-induced neuromuscular block (0.25 mg kg(-1)) were measured: onset time, maximum block, recovery to 25% first twitch height, recovery index (time from 25% until 75% recovery of first twitch), duration to recovery to a train-of-four (TOF) rate of 0.7 and 0.9.
The groups did not differ with regard to onset time, maximum block, and recovery index. The duration to 25% twitch height was significantly lower in Group A [18.1 (0-30.7) min] compared with Group B [23.5 (0-36.7) min; P<0.05]. Duration to a TOF rate of 0.7 and 0.9, respectively, were significantly reduced in Group A [36.1 (7.9) and 40.9 (9.0 min)] compared with Group B [47.9 (7.6) and 53.4 (9.2) min; P<0.001].
Long-term medication with prednisolone resulted in a shorter duration of an atracurium-induced neuromuscular block in patients with Crohn's disease or ulcerative colitis. The presence of the inflammatory bowel disease did not influence the time course of the neuromuscular block.
皮质类固醇与神经肌肉阻滞剂相互作用。然而,实验数据相互矛盾:已观察到神经肌肉阻滞增强和减弱的情况。本研究测试了泼尼松龙长期用药对阿曲库铵诱导的神经肌肉阻滞的影响。
对60例择期腹部手术的慢性炎症性肠病患者进行研究。30例患者接受泼尼松龙长期用药(A组),30例未使用皮质类固醇药物(B组)。此外,另30例无炎症性肠病且未使用皮质类固醇药物的患者作为对照(C组)。测量阿曲库铵诱导的神经肌肉阻滞(0.25mg/kg(-1))的以下参数:起效时间、最大阻滞、恢复至首次颤搐高度的25%、恢复指数(从首次颤搐的25%恢复至75%的时间)、恢复至四个成串刺激(TOF)比率为0.7和0.9的持续时间。
三组在起效时间、最大阻滞和恢复指数方面无差异。A组恢复至颤搐高度25%的持续时间[18.1(0 - 30.7)分钟]显著低于B组[23.5(0 - 36.7)分钟;P<0.05]。与B组[47.9(7.6)和53.4(9.2)分钟;P<0.001]相比,A组恢复至TOF比率0.7和0.9的持续时间分别显著缩短[36.1(7.9)和40.9(9.0)分钟]。
泼尼松龙长期用药使克罗恩病或溃疡性结肠炎患者阿曲库铵诱导的神经肌肉阻滞持续时间缩短。炎症性肠病的存在不影响神经肌肉阻滞的时间进程。